Open AccessSEQUENTIAL THERAPY OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: NEW POSSIBILITIES
Author(s) -
А. С. Маркова,
В. Б. Матвеев,
Б. М. Назранов
Publication year - 2018
Publication title -
onkourologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
H-Index - 4
eISSN - 1996-1812
pISSN - 1726-9776
DOI - 10.17650/1726-9776-2018-14-3-120-127
Subject(s) - medicine , prostate cancer , intensive care medicine , disease , medical prescription , oncology , cancer , pharmacology
Currently, doctors have at their disposal a number of drugs prolonging life of patients with castration-resistant prostate cancer (CRPC). The majority is approved for use as the 1st line therapy and, in absence of direct comparison, is considered potentially equally effective. Patients with CRPC need continuous treatment for suppression of disease progression resulting in sequential use of therapeutic agents. Modern standards and recommendations do not provide a clear algorithm for prescription, therefore an individual approach is necessary taking in account various factors of a particular case ranging from previous therapies to patients’ preferences. This article considers the most significant factors affecting CRPC therapy selection and ways of therapy optimization in compliance with the established treatment standards and taking into account the list of drugs approved for use in Russia.